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It is widely accepted that there are two principal forms of
cell death, namely, necrosis and apoptosis. According to
the classical view, necrosis is the major mechanism of
cardiomyocyte death in cardiac diseases.
Recent developments
In the past few years observations have been made showing
that cardiomyocyte apoptosis occurs in diverse conditions
including hypertensive heart disease, and that apoptosis
may be a contributing cause of loss and functional
abnormalities of cardiomyocytes in this condition.
Summary
This review will summarize recent evidence demonstrating
the potential contribution of cardiomyocyte apoptosis to
heart failure in hypertensive patients. In addition, some
strategies aimed to detect and prevent apoptosis of
cardiomyocytes will be considered.
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It has been classically accepted that adult cardiomyocytes
are not capable of proliferation and, thus, are resistant to
developing apoptosis. Thus, the existence of a balance
between apoptotic cell death and cell regeneration in the
heart has been denied until recently. In the past decade,
however, observations have been made showing that
cardiomyocyte apoptosis occurs in diverse conditions
[1,2]. One of these conditions is hypertensive heart
disease (HHD), here defined by the presence of a greater
than normal left ventricular mass in the absence of a cause
other than arterial hypertension and by the development
of complex changes in myocardial composition that are
responsible for the structural remodeling of the myo-
cardium (Table 1). One of these changes is a diminished
number of cardiomyocytes due to enhanced cell death,
including apoptotic cell death. In fact, cardiomyocyte
apoptosis has been shown to be abnormally stimulated
in the hypertrophied left ventricle of patients with essen-
tial hypertension, no angiographic evidence of coronary
artery disease and normal cardiac function [3,4]. In
addition, recent findings from our laboratory show that
cardiomyocyte apoptosis is increased in patients with
HHD and chronic heart failure compared with hyperten-
sive patients with HHD and normal cardiac function [5]
(Fig. 1). Thus, it seems that cardiomyocyte apoptosis
precedes the impairment in ventricular function and its
exacerbation accompanies the development of heart fail-
ure in patients with HHD.
Mechanistic links between cardiomyocyte
apoptosis and heart failure
in hypertensives
Arterial hypertension affects the myocardium at two
different stages [6]. In both humans and animal models,
pressure overload is characterized by a period of com-
pensation in which left ventricular concentric hypertro-
phy normalizes systolic wall stress and contractile
function is preserved. The period of adaptation, which
may last for weeks in rodents and months to years in
humans, is inexorably followed by a transition to cardiac
failure. This transition is characterized by impaired sur-
vival, the onset of chamber dilatation with the failure of
further concentric hypertrophic growth to normalize load,
and progressive contractile dysfunction. A number of
observations suggest that beside changes in the compo-
sition of motor unit and cytoskeleton of cardiomyocytes,
the transition from hypertrophy to failure relates mainly
to alterations in the histological composition of therized reproduction of this article is prohibited.
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Table 1 Main histological components of hypertensive myo-
cardial remodeling
Cellular changes
Hypertrophy of cardiomyocytes
Decreased number of cardiomyocytes
Increased number of fibroblasts
Phenotypic differentiation of fibroblasts into myofibroblasts
Presence of abundant inflammatory cells and mast cells
Noncellular changes
Interstitial and perivascular fibrosis
Wall thickening of intramyocardial vessels
Reduced number of capillariesmyocardium as a result of both alterations in the metab-
olism of extracellular matrix (namely, fibrillar collagen)
and cardiomyocyte loss due to multiple mechanisms of
death (including apoptosis). Beside reduction in the
number of cardiomyocytes, apoptosis may contribute
to heart failure through additional pathways [7,8]
(Fig. 2).
Apoptosis and structural and geometric remodeling
It has been suggested that alterations of the collagen
framework in the myocardium may play an important role
in the genesis of diastolic dysfunction of hypertensive
origin [9]. This has been supported by the finding that
fibrillar collagen deposition in the cardiac interstitium of
hypertensive patients increases left ventricular chamber
stiffness and compromises left ventricular filling during
diastole [10]. The problem concerns whether this type of
interstitial alteration occurs through activation of fibro-
blasts via humoral or mechanical factors in the absence of
cardiomyocyte loss, or whether cell death is required for
the stimulation of the growth response of the noncardio-
myocyte compartment of the myocardium. The obser-
vation that fibrosis is associated with cell loss in the left
ventricle of hypertensive patients [11] and patients withopyright © Lippincott Williams & Wilkins. Unauth
Figure 1 Cardiomyocyte (CM) apoptosis (left panel) and density (rig
cardiac function (non-heart failure) or clinical manifestations of he
Adapted from [5]aortic stenosis [12] raises questions about the mechanism
responsible for the modification of the interstitium with
accumulation of fibrillar collagen. As proposed by
Anversa et al. [13], death of individual cardiomyocytes
may stimulate discrete healing processes contributing to
the expansion of the interstitium. This proposal is further
supported by the experimental finding that failing hearts
from spontaneously hypertensive rats (SHR) present
colocalization of collagen a1 type I gene expression
to areas of focal cardiomyocyte degeneration [14],
suggesting that cardiomyocyte loss is associated with
collagen type I production and focal scar formation in
these animals during the transition from hypertrophy
to failure.
Besides histologic remodeling of the myocardium, cardio-
myocyte apoptosis may also contribute to geometric
remodeling of the left ventricular chamber. In fact, severe
cardiomyocyte apoptosis may lead to side-to-side slip-
page of cells, mural thinning and chamber dilatation.
Thus, wall restructuring secondary to severe cardiomyo-
cyte apoptosis may create an irreversible state of the
myocardium, conditioning progressive dilatation and
the continuous deterioration of cardiac hemodynamics
and ventricular performance with time [15].
Apoptosis and energy production
It is known that energy metabolism is deranged in the
human hypertensive and failing myocardium. Although
recent findings suggest that altered myocardial fatty acid
metabolism may account for this abnormality in hyper-
tensive patients [16], the possibility also exists that
mitochondrial production of adenosine triphosphate
(ATP) is diminished in the hypertensive myocardium
[17]. In this setting it is interesting to consider that
apoptosis is associated with loss of cytochrome c fromorized reproduction of this article is prohibited.
ht panel) in patients with hypertensive heart disease and normal
art failure (HF)
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Figure 2 Pathways to heart failure activated by increased car-
diomyocyte apoptosis in hypertensive heart disease
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availabilitythe mitochondria and this may halt oxidative phosphoryl-
ation and production of ATP, namely in subsarcolemmal
mitochondria [18]. Nevertheless, as apoptosis is an
energy-requiring process, in conditions of severely dimin-
ished ATP availability the mode of cell death would
switch to necrosis. One might then predict that apoptotic
stimuli do not necessarily induce complete loss of cyto-
chrome c from the mitochondria. Thus, the contribution
of the mitochondrial pathway of apoptosis to the energy
balance of the hypertensive myocardium remains to
be clarified.
Apoptosis and contractile mass
As previously mentioned, increased cardiomyocyte apop-
tosis and diminished cardiomyocyte number have been
found in the failing hearts of hypertensive patients [5].
This has been confirmed at the experimental level in
SHR with heart failure [19]. Thus, apoptosis may be one
of the mechanisms involved in the loss of contractile mass
and function in HHD. At present, however, there is no
information concerning the magnitude of cell loss
required to depress cardiac contractility in the hypertro-
phied human heart when cell death occurs. Although
most studies examining apoptosis in the end-stage heart
report variable but low apoptosis rates (0.1–0.5% of
cardiomyocytes), conservative assumptions about the
duration of apoptosis and the constancy of the implied
rate of cell death suggest that apoptosis could result in the
loss of up to 5–10% of the myocardium per year [20].
Although the progressive nature and poor survival in late-
stage heart failure may well be consistent with such a
substantial loss of cardiomyocytes, it means that the heart
should rapidly disappear. This contention, however, does
not consider that the adult heart possesses a stem cell
compartment that can regenerate cardiomocytes and
coronary vessels [21]. This does not imply that cellopyright © Lippincott Williams & Wilkins. Unauthoreplication compensates for the extent of apoptotic loss in
the diseased myocardium, but allows the hypothesis that
inadequate cardiomyocyte division may be a critical
event in the evolution of the pathological heart to heart
failure [22].
Apoptosis and contractility
Impaired myocardial contractile function may reflect not
only a decrease in the number of viable, fully functional
cardiomyocytes, but also a decrement in the function of
viable cardiomyocytes, or a combination of these mech-
anisms. It is well known that apoptosis is associated with
activation of caspases that mediate the cleavage of vital
and structural proteins. Caspase-3 cleaved cardiomyocyte
myofibrillar proteins resulting in an impaired force/Ca2þ
relationship and myofibrillar ATPase activity have been
reported [23]. In addition, it has been demonstrated that
caspase activation is associated with cleavage of myofila-
ments, disruption of sarcomeric structure and reduction
in contractile force of failing cardiomyocytes, and that
blockade of caspase activation improves contractility in
failing myocardium [24]. As apoptosis may not be com-
plete in cardiomyocytes, allowing the cells to persist for a
prolonged period within the myocardium, the detrimen-
tal effects of caspase activation on systolic function
should not be underestimated. This possibility is particu-
larly relevant taking into account that an intense expres-
sion of the active form of caspase-3 has been reported
in cardiomyocytes from patients with HHD and heart
failure [25].
Apoptosis and electrical activity
HHD is associated with increased incidence of both
ventricular arrhythmias and sudden cardiac death,
namely when heart failure is present [26]. It has been
proposed that cardiomyocyte apoptosis may contribute to
the development of arrhythmias in the failing heart
through two ways [27]. First, in the progress of dying,
a cardiomyocyte passes through phases of increased
excitability or becomes automatic, at least until it is dead.
Second, from a random grouping of several such dead
cells, the process of normal activation in that area of heart
muscle must be deranged and redirected in a way that
would provide a suitable anatomical substrate for re-
entrant arrhythmias.
Clinical recognition of cardiac apoptosis
Thus far, methods by which to measure apoptosis were
designed for in-vitro analysis. Most of these methods
require tissue biopsy specimens to be obtained from
the patient to retrieve information of apoptosis in situ.
This limits the application of these apoptosis detection
methods in clinical practice. A noninvasive detection
method by which to visualize apoptosis would be ideal
to assess its role in disease and to measure treatment
outcome in diseases such as HHD.rized reproduction of this article is prohibited.
CApoptosis in hypertensive heart disease Gonza´lez et al. 291Imaging studies
Some molecular changes characteristic of apoptosis have
been proposed as potential markers to be used in imaging
techniques (e.g. nuclear magnetic resonance and radio-
nuclide imaging) to detect previously inaccesible and
unrecognized biological phenomena in living cells and
tissues undergoing apoptosis [28,29].
For instance, apoptosis activates mechanisms which
cause the translocation of phosphatidylserine from the
internal to the external leaflet of the plasma membrane
[30]. Annexin V is a phospholipid binding protein, which,
in the presence of Ca2þ ions, specifically and reversibly
interacts with the phosphoserine headgroup of phospha-
tidylserine in the apoptotic cell [31] (Fig. 3). This prop-
erty has been the driving force for the research of annexin
V conjugated with a detectable marker, such as biotin, a
fluorochrome, or a radioligand, as a probe to measure
apoptosis in vitro and in vivo in animals and patients [32].
Technetium-99 m labeled annexin V has been success-
fully used for noninvasive g-imaging of cardiac apoptosis
after acute myocardial infarction, acute myocardial ische-
mia, acute cardiac allograft rejection and malignant intra-
cardiac tumors [33].
Biochemical assessment
Besides imaging studies, determination of circulating
annexin V may be also useful for the biochemical
monitoring of the apoptotic process. In this respect, it
has been reported in humans that plasma levels of
annexin V determined by means of ELISA are increased
8-fold in the early phase of acute myocardial infarction,
and immediately decrease after the onset of pain [34].
Other circulating markers of apoptosis are currently
under investigation. For instance, it has been recentlyopyright © Lippincott Williams & Wilkins. Unauth
Figure 3 The arrow signals an annexin V-positive cardiomyocyte
and the arrowhead signals a control nonstained cardiomyocyte
Annexin V staining was detected with tetramethylrhodamine-conjugated
extravidine.reported that during apoptosis cytochrome c not only
translocates into the cytosol but is secreted to the extra-
cellular medium [35]. Thus, its potential role as a serum
marker of cardiac apoptosis in chronic cardiomyopathies,
including HHD, remains to be investigated.
Therapeutic modulation of cardiac apoptosis
It has been postulated that the inhibition of cardiomyo-
cyte apoptosis could prevent or slow cardiac failure
progression, thus opening new strategies in the treatment
of cardiac diseases [36,37]. Cardiomyocyte apoptosis
may be inhibited by suppressing the systemic and local
factors that trigger the process, by directly blunting the
intracellular apoptotic pathways or by inducing the sur-
vival pathways.
Strategies aimed to blunt triggers of the
apoptotic process
The main systemic trigger of apoptosis to be considered
in HHD is arterial hypertension itself. The in-vivo effects
of antihypertensive drugs on cardiac apoptosis in SHR
have been reviewed elsewhere [38]. Collectively, the
available findings suggest that the ability of antihyper-
tensive drugs to inhibit cardiac apoptosis is independent
of their antihypertensive efficacy, but can be related to
their capacity to interfere with the pro-apoptotic actions
of humoral factors. This is further supported by clinical
findings showing that despite an identical antihyperten-
sive efficacy, the angiotensin II type 1 receptor antagonist
losartan, but not the Ca2þ channel blocker amlodipine,
reduced cardiomyocyte apoptosis in patients with HHD
after 1 year of treatment [4].
Oxidant stress is an important local factor inducing car-
diomyocyte apoptosis. Thus, antioxidant therapy,
whether through administration of additional antioxi-
dants or boosting innate antioxidant mechanisms, has
been shown to be a viable approach in reducing cardiac
apoptosis in experimental conditions [39,40]. In the
clinical setting, agents with antioxidant properties such
as carvedilol or those that promote antioxidant activity,
such as propranolol, are already used to treat patients with
heart failure [41]. One ongoing study is testing the effect
of oxypurinol, the major metabolite of the xanthine
oxidase inhibitor allopurinol, in patients with heart failure
[42]. The rationale for this study is that oxypurinol has
been reported to substantially improve the cardiac struc-
ture and function in SHR with heart failure [43] and that
xanthine oxidase has been identified as a source of
reactive oxygen species in patients with heart failure [44].
Strategies aimed to interrupt the apoptotic process
The past decade has witnessed tremendous progress
in the knowledge of the molecular mechanisms that
regulate and execute apoptosis at the intracellular level.
Consequently, apoptosis regulators and executors haveorized reproduction of this article is prohibited.
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Table 2 Potential molecular targets of the apoptotic machinery
At the level of the death receptor pathway
Blockade of the tumor necrosis factor receptor superfamily of
death receptors
Inhibition of adapter proteins
Inhibition of non-executioner caspases -8 and -10
At the level of the mitochondrial pathway
Inhibition of the pro-apoptotic Bcl-2 family members
Stimulation of the antiapoptotic Bcl-2 family members
Blockade of the release of cytochrome c in the cytosol
Blockade of the second-mitochondria-derived activator of caspases
Interruption of the assembly of Apaf-1 and the
non-executioner caspase-9
At the global level
Inhibition of the executioner caspases -3, -6, -7
Stimulation of the members of the inhibitor of apoptosis familyemerged as key targets for the design of therapeutic
strategies aimed at interrupting cellular death decisions
[36,45] (Table 2).
For instance, increased survivin (a member of the inhibi-
tor of apoptosis [IAP] family) myocardial expression in
aging SHR with heart failure is associated with reduced
cardiomyocyte apoptosis and more favorable echocardio-
graphic indexes of left ventricular remodeling and dys-
function [46]. On the other hand, overexpression of
human antiapoptotic protein Bcl-2 decreases cardiac
apoptosis and improves cardiac function in transgenic
mice after ischemia/reperfusion [47]. By contrast, tar-
geted deletion of pro-apoptotic members of the Bcl-2
protein family in a mouse model of cardiac ischemia/
reperfusion attenuated both apoptosis and necrosis [48].
Similar effects have been reported with low molecular
weight caspase inhibitors [49]. Interestingly, some of
these inhibitory compounds were effective not only in
reducing cardiomyocyte apoptosis but also in improving
cardiac function and delaying heart failure development
[50].opyright © Lippincott Williams & Wilkins. Unautho
Figure 4 Strategies to preserve the population of functional cardio
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+Other studies are focusing on the stimulation of the
ubiquitin–proteasome system that contributes to regu-
lation of apoptosis through the degradation of apopto-
sis-regulatory proteins. This is based on the recent
observation that depression of proteasome activities
in pressure-overloaded hearts of mice contributes to
cardiac dysfunction resulting from cardiomyocyte apop-
tosis through accumulation of pro-apoptotic proteins by
impaired degradation [51].
Strategies aimed to stimulate cellular
survival mechanisms
An alternative strategy to prevent cardiomyocyte apop-
tosis is the improvement of cellular survival mechanisms
[52]. For instance, cardiotrophin-1 has been shown to
protect cardiomyocytes against angiotensin II and oxi-
dative stress-induced cell death via gp130/LIFR and by
means of the PI3K/Akt and p42/44 MAPK intracellular
cascades [53]. These aspects can be of particular
relevance taking into account that molecular and func-
tional alterations of the gp130 survival pathway have
been described recently in failing human hearts [54].
Another important cardiomyocyte survival factor is insu-
lin-like growth factor-I (IGF-I). In fact, in-vitro and
in-vivo studies have shown that IGF-I decreases experi-
mentally induced cardiomyocyte apoptosis through the
activation of signaling pathways similar to those acti-
vated by cardiotrophin-1 [55]. Interestingly, in clinical
studies with patients with heart failure, IGF-I levels are
low and correlate with the severity of left ventricular
systolic dysfunction [56].
Novel therapeutic approaches
Several new treatment strategies are currently being
explored in chronic heart failure, which, among other
effects, have been shown to decrease cardiomyocyte
apoptosis either clinically or experimentally. Theserized reproduction of this article is prohibited.
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antagonists [57], calcium-sensitizing agents [58], statins
[59] and erythropoietin [60], and device therapy aimed to
induce cardiac resynchronization [61].
Conclusion
Numerous hypotheses have been considered to explain
the fundamental mechanism(s) for the development of
heart failure in patients with HHD. Cardiomyocyte loss
and dysfunction due to apoptosis is now being considered
as one of the determinants of the maladaptive processes
implicated in the transition from left ventricular hyper-
trophy to heart failure in hypertensive patients. Much
work is being carried out regarding the mechanisms and
the impact of cardiomyocyte apoptosis on the hyperten-
sive myocardium but several methodological and con-
ceptual issues still remain unsolved. Clarification of these
is extremely urgent if one considers that the development
of noninvasive tools for the monitoring of cardiac apop-
tosis and pharmacological strategies aimed to inhibit and/
or counteract the apoptotic process could be of particular
relevance to protect the cardiomyocyte and prevent the
progression to heart failure in patients with HHD (Fig. 4).
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